Results 221 to 230 of about 151,694 (306)

Ropeginterferon‐α2b in mycosis fungoides and Sézary syndrome: Safety and efficacy in 41 patients

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Pegylated interferon‐α2a became the off‐label alternative for treating mycosis fungoides/Sézary syndrome (MF/SS) after non‐pegylated interferons were withdrawn. This study aimed to evaluate the safety and efficacy of ropeginterferon‐α2b in MF/SS. Patients and methods We performed a retrospective multicenter analysis at
Stefanie Porkert, Juliette M. Kersten, Rosanne Ottevanger, Hanna Schratter, Regina Fink‐Puches, Van Anh Nguyen, Farzaneh Sadeghyar, Johanna Latzka, Franz Trautinger, Magdalena Hoellwerth, Peter Koelblinger, Nicole Pfannschmidt, Nina Haering, Johannes Griss, Maarten H. Vermeer, Constanze Jonak   +15 more
wiley   +1 more source

Prenatal diagnosis of glucose-6-phosphatase catalytic subunit 3 deficiency (Dursun syndrome) using whole-exome sequencing: A case report of severe fetal cardiomyopathy in a consanguineous family. [PDF]

J Int Med Res
Ghazali SM, Bader RS.
europepmc   +1 more source

Analysis of an Age-Structured Model of Chemotherapy-Induced Neutropenia [PDF]

, 2014
Safranek, Lee Joseph
core  

Inborn errors of immunity in children with neuroinflammation

Developmental Medicine &Child Neurology, EarlyView.
Abstract Inborn errors of immunity (IEIs), an expanding group of monogenic disorders with diverse clinical manifestations, are increasingly recognized to include neuroinflammatory disease. Examples of diseases included under this umbrella are Aicardi–Goutières syndrome, deficiency of adenosine deaminase 2, familial haemophagocytic lymphohistiocytosis ...
Eppie M Yiu, Dilan Dissanayake, Jessie Cunningham, Helen Branson, Ori Scott, E Ann Yeh   +5 more
wiley   +1 more source

Platelet counts, but not neutrophil counts, are associated with non-bleeding-related mortality in patients with hematological malignancies and post-chemotherapy febrile neutropenia. [PDF]

Hematol Transfus Cell Ther
Salioni GR, Moraes CRP, da Silva LQ, Mayr E, Duarte BKL, De Paula EV.   +5 more
europepmc   +1 more source

Early tocilizumab and outcomes in acute necrotizing encephalopathy

Developmental Medicine &Child Neurology, EarlyView.
Early tocilizumab and outcome in acute necrotising encephalopathy. Aim To evaluate the timing and safety of tocilizumab in acute necrotizing encephalopathy (ANE). Method This was a multicentre retrospective study evaluating outcomes (modified Rankin Scale [mRS]) in children with ANE treated with tocilizumab. A logistic regression model determined a cut‐
Velda X Han, Prithuja Poudyal, Vanessa Lee, Arushi Gahlot Saini, Shekeeb S Mohammad, Sekhar C Pillai, Gouri Rao Passi, Naveen Sankhyan, Ahmad Rithauddin Mohamed, Lokesh Lingappa, Hiroshi Sakuma, Russell C Dale, Ming Lim, Terrence Thomas, for The International ANE Study Group   +14 more
wiley   +1 more source

Systematic Duffy phenotyping reveals high prevalence of Duffy-null genotype among neutropenic patients. [PDF]

Adv Lab Med
Sierra LS, Núñez NF, Querol MS, Arnall AM.   +3 more
europepmc   +1 more source

Venous Thromboembolism in Hematologic Malignancies: Incidence, Risk Factors, and the Role of Direct Oral Anticoagulants

European Journal of Haematology, EarlyView.
ABSTRACT Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.
Mario Biglietto, Silvia Sorella, Erminia Baldacci, Massimo Breccia, Sabina Chiaretti, Marcello Capriata, Livia Donzelli, Gianna Maria D'Elia, Salvatore Giacomo Morano, Ilaria Del Giudice, Maurizio Martelli, Cristina Santoro, Antonio Chistolini   +12 more
wiley   +1 more source

Humoral Immune Abnormalities in Transient Childhood Neutropenia: Insights From a 10-year Cohort Study in a Tertiary Center. [PDF]

J Clin Immunol
Schorn E, Soomann M, Prader S, Pachlopnik Schmid J, Trück J.   +4 more
europepmc   +1 more source

Feasibility and Safety of Venetoclax for Cytoreduction During Induction Therapy in Newly Diagnosed Acute Promyelocytic Leukemia

European Journal of Haematology, EarlyView.
ABSTRACT Objective This study aimed to evaluate the feasibility and safety of venetoclax as a cytoreductive strategy during induction therapy in newly diagnosed acute promyelocytic leukemia (APL), and to provide an exploratory description of its early efficacy.
Yu Wang, Rong Xiao, Xiaobing Huang, Yi Xiao   +3 more
wiley   +1 more source